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ABSTRACT
Introduction  Psoriasis susceptibility locus 4 (PSORS4) 
is a susceptibility locus for psoriasis vulgaris (PsV), a 
common inﬂ  ammatory, hyperproliferative skin disorder. 
Recently, a deletion of 2 late corniﬁ  ed envelope (LCE) 
genes within epidermal differentiation complex on 
chromosome 1 was shown to be enriched in 1426 
patients with PsV, suggesting compromised barrier 
function in deletion carriers. This genetic association was 
subsequently conﬁ  rmed in a German cohort.
Methods  In order to investigate whether this variant 
also predisposes to psoriatic arthritis (PsA), this deletion 
and 3 single nucleotide polymorphisms (SNPs) in strong 
linkage disequilibrium with it were genotyped in a case-
control cohort of 650 patients and 937 control individuals 
of German origin.
Results  LCE deletion frequency did not signiﬁ  cantly 
differ between patients with PsA and controls (65.0% vs 
65.5%). Similarly, no evidence for association to the three 
SNPs was observed.
Discussion  This is the ﬁ  rst non-human leucocyte 
antigen (HLA) risk factor predisposing only to skin type of 
psoriasis, supporting the concept of partially overlapping 
but different aetiological factors underlying skin and joint 
manifestations.
INTRODUCTION
Psoriasis vulgaris (PsV) is a common inﬂ  ammatory 
skin disorder characterised by epidermal hyper-
proliferation, altered keratinocyte differentiation and 
immunological processes (for example, invasion of 
granulocytes and of T cells in affected skin). About 
30% of patients1 develop an inﬂ  ammatory joint dis-
ease, designated as psoriatic arthritis (PsA). Although 
the relative recurrence risk for relatives of patients 
with PsA is 3.5–13 times higher as compared with 
those of patients with PsV,2–6 indicating an even stron-
ger genetic impact in PsA, most genetic risk factors 
identiﬁ  ed for psoriasis so far; for example, variants 
in the interleukin 23 receptor (IL23R) pathway7 and 
variants in the genes NAT9, SLC9A3R1 and RAPTOR 
at psoriasis susceptibility locus 2 (PSORS2) on chro-
mosome 17q258 do not account for the differences 
in, for example, sibling recurrence risk, or explain the 
different organ manifestations. It is of note, though, 
that frequency differences in the human leucocyte 
antigen (HLA)-C risk allele have been observed 
between patients with PsV and PsA.9–13
PSORS4 was identiﬁ  ed in a genome-wide linkage 
analysis,14 and this locus is of special interest for 
PsV since it comprises the epidermal differentiation 
complex (EDC), a group of genes expressed in the 
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upper strata of the epidermis. While several genes 
at PSORS4 (for example, LOR, LCE1C, PGLYRP, 
SPRR genes, PRR9 genes and IVL) have been pro-
posed to account for psoriasis susceptibility,15–18 
very recently, a copy number variation (CNV) 
within the late corniﬁ  ed envelope (LCE) gene clus-
ter was identiﬁ  ed by a genome-wide scan using 
pooled DNAs. The deletion of 2 late corniﬁ  ed 
envelope genes (LCE3C and LCE3B) was shown to 
be enriched in 1426 patients with psoriasis and to 
be associated in a large family-based cohort.19 The 
results of the same study suggested that carriers of 
the deletion have a compromised repair response 
following barrier disruption in the skin.19
In the present work, we were interested in inves-
tigating whether the LCE deletion also contributes 
to susceptibility to PsA.
METHODS
We analysed a large case-control study compris-
ing 650 patients with PsA, a subset of the 748 
patients previously described.7 For this subset high-
  quality DNA from Qiagen column puriﬁ  cation 
was available (Qiagen, Hilden, Germany). All 650 
patients fulﬁ  lled the recently deﬁ  ned CASPAR (for 
‘ClASsiﬁ  cation of Psoriatic ARthritis’) criteria and 
were recruited by board certiﬁ  ed rheumatologists. 
In comparison to the previously described, larger 
cohort,7 clinical characteristics were very similar: 
the mean (SD) age of onset for PsV was 28.2±13.0 
years; 61.9% of the patients were men. For 78% 
of the patients, the diagnosis of PsA was made 
≥3 years before recruitment and 96% of patients 
had a skin involvement ≥3 years before recruit-
ment. Peripheral joint involvement was detect-
able in the majority of cases (619 or 95.2%); this 
was oligoarticular in 141 patients and polyarticu-
lar in 474 (21.7% and 72.9% of the entire cohort, 
respectively). Diagnosis of spinal involvement was 
based on symptoms of inﬂ  ammatory back pain, 
characteristic clinical signs of restricted vertebral 
movement and/or sacroiliac pain upon physical 
examination, and a subsequent conﬁ  rmation  by 
radiographic signs of either sacroiliitis and/or spon-
dylitis. Spinal involvement was observed in 132 
patients, accounting for 20.3% of the PsA cohort. 
In these patients, sacroiliits or spondylitis or both 
were partly associated with concomitant periph-
eral joint disease. The 937 control individuals were 
the same as previously reported.
We genotyped the CNV with a modiﬁ  ed protocol 
from that used by Cid et al,19 a multiplex assay of 
two ﬂ  uorescently marked PCR products detected 
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on an ABI3730 DNA sequencer (Applied Biosystems, Foster City, 
California, USA). Brieﬂ  y, we ampliﬁ  ed a breakpoint-spanning 
PCR product of 351 bp (F: GGATACTAAGAAGTTCTCAC; 
R: GTGGTGAGAGAGGGCATCTC) for deletion alleles and 
a second amplicon for wild-type alleles (primers within the 
deleted region, product size of 561 bp (F: CATTAGCCTGG
AGCTTTTGC; R: ACAAGTGATAACATTGTCAGGAGG)) 
using Amplitaq Gold polymerase (Applied Biosystems) and 
40 ng DNA. The multiplex reaction was diluted 1:20; 5 μl were 
analysed with size standard LIZ600 (Applied Biosystems) on 
the capillary sequencer. Genotypes passing quality control 
showed peak intensities >2000 ﬂ  uorescent units, and in puta-
tive heterozygote individuals, ratios of LCE3C-LCE3B-del allele 
to non-deletion allele peak heights were >0.5 and <3. To esti-
mate the error rate  of genotyping, we performed duplicate 
genotyping of six 96-well microtitre plates. In all, 515 DNAs 
yielded ampliﬁ  cation in both runs and were used to compare 
genotypes. Within these, 449 (87.2%) passed both quality crite-
ria (see earlier) and were concordant in both experiments. Seven 
DNAs (1.4%) passed quality control in both runs, but showed 
divergent genotypes. We therefore have to assume a genotyp-
ing error rate of about 1.4 %. Since it is not known whether the 
genetic risk factor is the deletion or a variant in strong linkage 
disequilibrium (LD), we also genotyped three single nucleotide 
polymorphisms (SNPs) (rs10888502, rs4112788, rs4845456) in 
the same LD block. SNPs were genotyped using TaqMan assays 
(Applied Biosystems). In addition, 72 randomly selected geno-
types were veriﬁ  ed by DNA sequencing single individuals as 
previously described.
RESULTS AND DISCUSSION
For all variants, Hardy–Weinberg equilibrium was fulﬁ  lled in 
both groups of patients and control individuals. Genotyping rates 
of  LCE3C-LCE3B-del, rs10888502, rs4112788 and rs4845456 
were between 94.1% and 96.4%. Almost all variants were in 
perfect LD with each other, except for LD between the CNV 
and rs10888502. We observed similar allele frequencies for all 
variants in patients and control individuals; differences were 
not signiﬁ  cant as determined by χ2 statistics (table 1). Similar 
results were obtained for haplotypes that were calculated using 
Haploview20 (data not shown).
A power analysis revealed that we have 95% power to detect 
a risk factor with an allele frequency of 68% to 72% and an OR 
of 1.37 to 1.38 in our case-control cohort under the assumption 
of a logarithmic-additive model and with a type I error rate of 
5% (calculated with Quanto).21 Considering that initial studies 
often overestimate effects of risk factors, we determined that 
we had power of 80% of detecting an association even for an 
OR of 1.22 to 1.23 under the assumption of an identical allele 
frequency range.
The lack of association is most probably not due to the geo-
graphical origin of the patients, as we identiﬁ  ed highly signif-
icant association to the deletion in an independent study of 
patients with PsV without joint manifestation retrieved from 
the same population (Germany)22 similar in magnitude to that 
recently reported.19 Likewise, we did not observe evidence for 
association in the subset of 502 patients with PsA with manifes-
tation ≤40 years of age (type I psoriasis) and average age of onset 
in the subset was comparable to the one of the above mentioned 
PsV cohort ((24.0±9.5 and 23.2±11.9, respectively). Finally, no 
evidence for association was observed in subgroups of carriers 
or non-carriers of the PSORS1 risk allele.
Given the almost identical allele frequencies between both 
groups, it is highly unlikely, that the genotyping error deter-
mined can account for the lack of association. Our results sug-
gest that the LCE3C-LCE3B-del, primarily identiﬁ  ed in patients 
with skin type psoriasis, does not predispose to joint manifes-
tation at least in German patients. Therefore this susceptibility 
factor is more speciﬁ  c to the skin manifestation than most of 
the risk factors for psoriasis identiﬁ  ed, to date. Accordingly, our 
ﬁ  nding is also experimental support for the concept that besides 
common genetic factors, also clearly distinct ones contribute to 
the aetiology of distinguishable clinical manifestations such as 
psoriasis of skin and joints.
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